Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.

Vijay Kumar Anand Prakash SinghNicholas WheelerCristi L GalindoJong-Joo Kim

Published in: Expert opinion on drug safety (2021)

Patients taking D-pen require close monitoring of renal function, blood counts, immunity, liver, cardiac function, and neurological function. D-pen suppresses immune system which maximizes the risk of infection.

Keyphrases

adverse drug
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
signaling pathway
peritoneal dialysis
drug induced
subarachnoid hemorrhage
cerebral ischemia